Remission of diabetes while on sunitinib treatment for renal cell carcinoma.
Templeton
A
A
Brändle
M
M
Cerny
T
T
Gillessen
S
S
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000150:complications / Q000188:drug therapy*; D003713:Dendritic Cells; D048909:Diabetes Complications / Q000517:prevention & control; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007211:Indoles / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage*; D007680:Kidney Neoplasms / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D000077210:Sunitinib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007211:Indoles; D007328:Insulin; D011758:Pyrroles; D000077210:Sunitinib